This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDOs national lifesciences co-leader, details the Biosecure Act, including the ways pharmacompanies are preparing for it, especially from a compliance standpoint.
In 2023, there were significant advancements and notable trends in the lifesciences. Xtalks compiled a list of its top lifescience news and trends of 2023, which provided readers with the latest developments, information and expert insights across lifescience industries, including pharma, biotech and medical device.
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. His operational responsibilities will include channel management, compliance services, field deployment solutions, and patient services. Read on for the hires headlines.
According to Alex Edwards, solutions architect at leading pharmaceutical translations provider RWS: “Pharmacompanies have three years until EU-CTR is mandatory, but it's in everyone's interest to start sooner rather than later. Right now, we're positioning RWS as the go-to provider for the creation and assessment of lay summaries.”.
Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in lifesciences, and rightly so because HCPs’ needs and expectations have changed. “There isn’t a one-size-fits-all for how the lifesciences industry creates content.
86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating a greater volume of content now, compared to six months ago. To assist executives in lifesciences with scaling marketing assets in a virtual world Veeva has published a new eBook, Powering Omnichannel Strategies with Modular Content.
Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from lifesciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a lifesciences future very much immersed in speciality medicine?
The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharmacompanies. The company was selected for its industry leading Virtual Care Management (VCM) program.
People who trust pharma are more interested in using the industry’s services – making building confidence in the sector key to realising the potential of patient centricity. However, according to Jennifer Turcotte, pharma advisor in the company’s healthcare and lifesciences division, there was also some good news.
Companies outsource to gain access to specialized expertise and technology, scale pharmacovigilance (PV) activities, and reduce costs. However, the efficiency and effectiveness of externalized safety activities are below expectations for many biotech and pharmacompanies.
UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. It’s been eventful 12-month period for the UK biotech guru Clive Dix, who has just seen his company C4X Discovery clinch a major inflammatory diseases deal with Sanofi.
Invasive options mainly surgeries that involve the injection of therapeutic agents into the anal canal or surgical repair of anal canal are often associted with patient relctance and non-compliance. However, pharmacompanies have taken the lead to expand in the Fecal Incontinence therapy market.
Over the years, his career has evolved from routine case processing at large pharmacompanies to a more strategic role in smaller settings, where he feels his impact more directly. Collaboration: The Key to Success The essence of pharmacovigilance at small companies according to Ashish, lies in teamwork.
They discussed current challenges and solutions that lifesciencecompanies and clinical development organizations have with the management of clinical data. To produce ethical results in a timely manner, lifesciencecompanies should ensure that they have a robust and reliable clinical data pipeline in place.
Creating personalised, compliant content is becoming increasingly important for lifesciencecompanies as HCPs demand more from their digital content. Pharmacompanies created 3.5 Guidance for creating and maintaining compliance. Veeva is the global leader in cloud software for the lifesciences industry.
It’s our representation of tracking the deidentified, which is important from a privacy and compliance point of view,” Sun says. “It During the pandemic, numerous digital health companies flourished due to the necessity for virtual solutions, including Komodo Health. About the author.
Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharmacompanies’ customer communication methods require reimagining as technology progresses. About the author.
Lastly, make the most of technology to streamline and minimise compliance risks, so your team can engage and manage communication effectively. Rethinking pharma’s events’ strategy. During the short period in which these changes occurred there was a steep learning curve for pharmacompanies trying to run digital events productively.
To compete now, companies need to own a larger portion of the treatment journey and the overall patient care experience. Commercial leaders should leverage the internal capabilities and centres of excellence that pharmacompanies are increasingly building.
The possibilities are endless, and in the context of trial participation and access to medicine technologies could assist: Reduced assessment times and hence increased patient compliance. There is a huge opportunity for pharmacompanies to capitalise on by focusing on increased DEI in clinical trials. What comes next?
Pre-commercial & Emerging pharmacompanies may not think they have the resources to match the launch strategies of big pharma. He takes us through the challenges of a successful launch and explains what pre-commercial companies need to focus on to hit their goals. “Ad-hoc approaches are not an option anymore.
A way to ensure compliance is to make sure the voice is not recorded but analysed and the full text is purged in real-time, leaving only the summarised call notes. Pharmacompanies and sales reps need to adapt to their customer behaviours to stay relevant”. This can overcome any privacy concerns. But it doesn’t stop there.
Especially in the field of Pharmaceutical & LifeSciences, a company’s all-around product life-cycle stages, which consist of planning, designing, constructing, product testing, and commissioning processes are provided by a Pharma Consultant. Pharma Consultant. Market Assessment & Operational Sales.
Transformative healthcare events can be fluid and can reshape the healthcare ecosystem, but the question of how deep and wide the impact will be is what healthcare continues to grapple with in planning and actions,” said Shankar Narayanan, CEO of Real Chemistry.
Blockchain can enhance data security and compliance by creating immutable data records. As such, there has been a continued rise in audits and inspections to ensure compliance with Good Clinical Practice (GCP) guidelines, reflecting a more rigorous regulatory environment in response to advanced trial methodologies.
XTALKS WEBINAR: Impacts of the New IVD Regulation (IVDR) for Manufacturers and Users Live and On-Demand: Tuesday, January 9, 2024, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn about the specific compliance requirements, risk assessments and quality management changes mandated by the IVDR.
Quality assurance (QA) plays a vital role across industries like lifesciences, food, medical devices and healthcare. QA ensures that products, systems and processes meet stringent standards for safety, efficacy and compliance, safeguarding consumers and elevating industry standards.
Moreover, such therapies have been shown to have a profound impact on patient compliance as well as therapy adherence, where the patients can self-administer the drugs. She holds a bachelors degree in Pharmaceutical Sciences which has provided her with a solid foundation in the ever-growing domain of life-sciences.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content